Adasuve 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0033 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
01/09/2022 
31/10/2022 
SmPC, Annex 
new quality, preclinical, clinical or pharmacovigilance 
data 
II, Labelling 
and PL 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
07/04/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
loxapine (pre-dispensed inhalation powder) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
II/0032 
C.I.13 - Other variations not specifically covered 
06/05/2021 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0030 
Submission of the category 3 final report from Drug 
14/06/2019 
n/a 
Utilization study AMDC-204-403 EU (A Multinational 
Retrospective Medical Record Review to Evaluate 
Utilization Patterns of Adasuve-Staccato loxapine for 
inhalation in agitated persons in routine clinical 
care). In addition, the MAH also submitted the 
second report with results of the healthcare 
professional survey on the effectiveness of the 
additional risk minimisation measures in Annex 7 of 
the RMP submitted with this variation. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
N/0031 
Minor change in labelling or package leaflet not 
13/05/2019 
31/10/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
14/03/2019 
n/a 
PRAC Recommendation - maintenance 
/201808 
loxapine (pre-dispensed inhalation powder) 
IB/0029 
C.I.11.z - Introduction of, or change(s) to, the 
20/02/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0027 
B.I.a.2.e - Changes in the manufacturing process of 
22/11/2018 
n/a 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Minor change to the restricted part of an 
ASMF 
N/0026 
Minor change in labelling or package leaflet not 
07/11/2018 
31/10/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
08/03/2018 
n/a 
PRAC Recommendation - maintenance 
/201708 
loxapine (pre-dispensed inhalation powder) 
R/0024 
Renewal of the marketing authorisation. 
09/11/2017 
15/01/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Adasuve in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IA/0023 
A.4 - Administrative change - Change in the name 
24/05/2017 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
09/03/2017 
n/a 
PRAC Recommendation - maintenance 
/201608 
loxapine (pre-dispensed inhalation powder) 
IB/0022 
C.I.11.z - Introduction of, or change(s) to, the 
21/02/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
N/0021 
Update of the package leaflet with revised contact 
28/11/2016 
15/01/2018 
PL 
details of the local representatives for Denmark, 
Finland, Iceland, Norway, Sweden and Cyprus. In 
addition, the MAH took the opportunity to make 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
minor linguistic amendments in the Danish labelling 
and in the Czech, Danish, Icelandic, Norwegian and 
Swedish package leaflets. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
17/03/2016 
n/a 
PRAC Recommendation - maintenance 
/201508 
loxapine (pre-dispensed inhalation powder) 
N/0018 
Minor change in labelling or package leaflet not 
28/10/2015 
15/01/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
10/09/2015 
n/a 
PRAC Recommendation - maintenance 
/201502 
loxapine (pre-dispensed inhalation powder) 
T/0017 
Transfer of Marketing Authorisation 
13/08/2015 
25/08/2015 
SmPC, 
Labelling and 
PL 
IB/0016/G 
This was an application for a group of variations. 
06/07/2015 
25/08/2015 
SmPC 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IAIN/0014 
C.I.8.a - Introduction of or changes to a summary of 
02/06/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0015 
B.II.b.3.a - Change in the manufacturing process of 
28/05/2015 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
PSUSA/10113
Periodic Safety Update EU Single assessment - 
12/03/2015 
n/a 
PRAC Recommendation - maintenance 
/201408 
loxapine (pre-dispensed inhalation powder) 
IAIN/0012 
C.I.8.a - Introduction of or changes to a summary of 
08/12/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0010/G 
This was an application for a group of variations. 
23/10/2014 
25/08/2015 
SmPC, 
Labelling and 
PL 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0009 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
25/09/2014 
25/08/2015 
SmPC 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUV/0007 
Periodic Safety Update 
11/09/2014 
n/a 
PRAC Recommendation - maintenance 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0008 
C.I.8.a - Introduction of or changes to a summary of 
05/06/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0006 
To extend the shelf life of the finished product from 
08/04/2014 
03/06/2014 
SmPC 
24 to 36 months. The applicant took the opportunity 
to revise the shelf life specifications of the finished 
product in order to bring them in line with the 
stability protocol. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUV/0005 
Periodic Safety Update 
06/03/2014 
n/a 
PRAC Recommendation - maintenance 
IAIN/0004 
C.I.8.a - Introduction of or changes to a summary of 
16/12/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0003 
C.I.9.c - Changes to an existing pharmacovigilance 
28/05/2013 
n/a 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
IB/0002/G 
This was an application for a group of variations. 
03/05/2013 
03/06/2014 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
Labelling and 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IAIN/0001/G 
This was an application for a group of variations. 
17/04/2013 
n/a 
C.I.9.b - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change in the 
contact details of the QPPV 
C.I.9.g - Changes to an existing pharmacovigilance 
system as described in the DDPS - Change of the site 
undertaking pharmacovigilance activities 
C.I.9.h - Changes to an existing pharmacovigilance 
system as described in the DDPS - Other change(s) 
to the DDPS that does not impact on the operation of 
the pharmacovigilance system 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
